yahoo_financeOriginal article
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
Phase 3positiveAtogepantPositive
AI Analysis
Summary
AbbVie's atogepant achieved its primary endpoint in a late-stage clinical trial for menstrual migraine treatment. This positive Phase 3 result supports the drug's development toward potential regulatory submission.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary goal in late-stage study
Importance:7/10
Sentiment:
0.80
Phase 3menstrual migrainepositive trial dataatogepant
Related Companies
Read the original article
Published by yahoo_finance on September 11, 2026 2:22 PM